Hematopoietic and lymphoid system neoplasm
MONDO:0002334Neoplasms of the hematopoietic system, including hematopoietic cell neoplasms (e.g. leukemias, lymphomas) and non-hematopoietic cell neoplasms that can affect the hematopoietic system (e.g. lymph node and splenic sarcomas). --2003
Also known as: haematopoietic neoplasm, haematopoietic neoplasm (morphologic abnormality), hematologic neoplasm, hematopoietic neoplasm, hematopoietic neoplasm (morphologic abnormality), blood neoplasm (disease), blood tumor, blood tumour
7617 clinical trials for this condition and its sub-types, 692 tagged with Hematopoietic and lymphoid system neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hematopoietic and lymphoid system neoplasm
-
Hematopoietic and lymphoid cell neoplasm 486 trials · 5,943 incl. sub-types
8 sub-types
- Lymphoid neoplasm 11 trials · 4,272 incl. sub-types Sub-types →
- Myeloid neoplasm 48 trials · 2,708 incl. sub-types Sub-types →
- Leukemia 361 trials · 2,566 incl. sub-types Sub-types →
- Refractory hematologic cancer 62 trials · 310 incl. sub-types Sub-types →
- Central nervous system hematopoietic neoplasm 0 trials · 107 incl. sub-types Sub-types →
- Histiocytic and dendritic cell neoplasm 10 trials · 99 incl. sub-types Sub-types →
- Myelodysplastic syndrome with excess blasts 72 trials · 84 incl. sub-types Sub-types →
- Myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2 0 trials · 4 incl. sub-types Sub-types →
-
Lymphoid hemopathy 0 trials · 4,285 incl. sub-types
4 sub-types
- Lymphoma 609 trials · 4,252 incl. sub-types Sub-types →
- Histiocytic and dendritic cell neoplasm 10 trials · 99 incl. sub-types Sub-types →
- Persistent polyclonal B-cell lymphocytosis 5 trials
- Immunodeficiency-associated lymphoproliferative disease 1 trial Sub-types →
-
Myeloid hemopathy 0 trials · 1,765 incl. sub-types
4 sub-types
- Myeloproliferative neoplasm 166 trials · 1,632 incl. sub-types Sub-types →
- Myelodysplastic syndrome 655 trials · 673 incl. sub-types Sub-types →
- Myelodysplastic/myeloproliferative disease 31 trials · 206 incl. sub-types Sub-types →
- Myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2 0 trials · 4 incl. sub-types Sub-types →
-
Bone marrow neoplasm 3 trials · 1,633 incl. sub-types
1 sub-type
- Bone marrow cancer 2 trials · 1,633 incl. sub-types Sub-types →
-
Thymus neoplasm 5 trials · 240 incl. sub-types
4 sub-types
- Thymus cancer 10 trials · 225 incl. sub-types Sub-types →
- Thymic epithelial neoplasm 14 trials · 56 incl. sub-types Sub-types →
- Thymic neuroendocrine tumor 3 trials · 6 incl. sub-types Sub-types →
- Benign neoplasm of thymus 0 trials Sub-types →
-
Spleen neoplasm 0 trials · 232 incl. sub-types
3 sub-types
- Marginal zone lymphoma 213 trials · 232 incl. sub-types Sub-types →
- Spleen cancer 0 trials · 2 incl. sub-types Sub-types →
- Benign neoplasm of spleen 0 trials Sub-types →
-
Lymph node neoplasm 5 trials · 60 incl. sub-types
3 sub-types
- Lymph node cancer 1 trial · 56 incl. sub-types Sub-types →
- Benign neoplasm of lymph node 0 trials
- Lymph node palisaded myofibroblastoma 0 trials
-
Cavernous hemangioma 1 trial
7 sub-types
- Cavernous hemangioma of colon 0 trials
- Cavernous hemangioma of face 0 trials Sub-types →
- Cavernous hemangioma of orbit 0 trials
- Dermal unilateral segmental cavernous angioma 0 trials
- Giant hemangioma 0 trials
- Intracranial cavernous angioma 0 trials
- Liver cavernous hemangioma 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1239 trials in this tab.
-
Can a Chemo-Transplant combo rescue patients whose leukemia resists standard treatment?
Cure CompletedThis trial tests a treatment strategy for adults with acute myeloid leukemia (AML) that did not respond to standard induction chemotherapy. Participants receive clofarabine and intermediate-dose Ara-C chemotherapy, followed by a reduced-intensity allogeneic stem cell transplant u…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Softer chemo before stem cell transplant aims to cure blood cancers in frail children
Cure CompletedResearchers test a reduced-toxicity conditioning regimen before allogeneic stem cell transplant in children and young adults with blood cancers. The regimen combines fludarabine, full-dose busulfan, and anti-thymocyte globulin. The trial measures transplant-related mortality at o…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Gentler transplant prep aims to cure tough blood cancers
Cure CompletedResearchers test a reduced-intensity conditioning regimen before allogeneic stem cell transplant in adults with high-risk AML, MDS, or ALL who cannot tolerate standard intensive treatment. The regimen combines clofarabine, busulfan, and thymoglobulin. The trial measures relapse r…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Softer chemo before stem cell transplant aims to save more blood cancer patients
Cure CompletedResearchers test a gentler conditioning regimen before allogeneic stem cell transplantation in adults with blood cancers. The goal is to see if this reduced-toxicity approach lowers the risk of death within the first year after transplant. Participants receive fludarabine, busulf…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Can an immunotherapy combo boost remission in a rare lymphoma?
Cure CompletedThis phase II trial is testing whether adding the immunotherapy drug tislelizumab to a chemotherapy regimen (pegaspargase, gemcitabine, and oxaliplatin) plus radiation can improve outcomes for people with early-stage, intermediate- or high-risk extranodal NK/T-cell lymphoma. The …
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
Vaccine aims to train immune system against blood cancers
Vaccine CompletedResearchers are testing a vaccine called 3D189 in adults with blood cancers such as acute leukemia, multiple myeloma, non-Hodgkin lymphoma, and higher-risk myelodysplastic syndrome. Participants must be in remission after standard treatment and unable to receive a stem cell trans…
Phase 1 • Sponsor: 3D Medicines • Aim: Vaccine
Last updated Sep 11, 2026 00:00 UTC
-
Does the pfizer vaccine work as well in immunosuppressed people? new study aims to find out
Vaccine CompletedThis study looked at how well the Pfizer mRNA vaccine triggers an immune response in people with weakened immune systems compared to healthy individuals. About 539 adults received two doses of the vaccine, and researchers measured antibody levels and side effects. The goal was to…
Phase 4 • Sponsor: Karolinska University Hospital • Aim: Vaccine
Last updated Jun 27, 2026 08:01 UTC
-
Experimental drug boosts Cancer-Killing cells in lymphoma trial
Disease control CompletedThis early-phase trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves 27 adults and focuses on safety and how w…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
Disease control CompletedResearchers are running a Phase I trial of HG146, an experimental oral drug, in adults with advanced solid tumors or lymphoma that have worsened despite standard treatments. The study first tests HG146 alone to find a safe dose, then tests it combined with a PD-(L)1 antibody, a t…
Phase 1 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
New pill shows promise for tough blood cancers in early trial
Disease control CompletedThis early-stage study tests a new drug, BGB-11417, in 64 adults with B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for signs that the drug shrinks …
Phase 1 • Sponsor: BeiGene • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Two-Drug chemotherapy combo tested against rare histiocytosis in adults
Disease control CompletedLangerhans cell histiocytosis is a rare disease in which immune cells called Langerhans cells build up in organs and cause damage. This phase 2 trial gives adults newly diagnosed with the disease a combination of two chemotherapy drugs, methotrexate and cytosine arabinoside (cyta…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Can a p53-Targeting drug boost chemotherapy in Hard-to-Treat blood cancers?
Disease control CompletedResearchers are testing a drug called APR-246 combined with azacitidine in people with myeloid blood cancers that carry a TP53 mutation, including myelodysplastic syndrome, acute myeloid leukemia, myeloproliferative neoplasms, and chronic myelomonocytic leukemia. The trial aims t…
Phase 1/2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Triple drug combo targets Hard-to-Treat brain lymphoma
Disease control CompletedResearchers are testing a combination of rituximab, acalabrutinib, and durvalumab in adults with primary central nervous system lymphoma, a rare cancer that starts in the brain or spinal cord. The trial enrolls people whose disease has returned or worsened after earlier treatment…
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can an oral drug slow a rare thymus cancer?
Disease control CompletedResearchers are testing whether lucitanib, an oral drug, can slow the growth of advanced thymic carcinoma that has worsened after at least one round of chemotherapy. The trial enrolls adults with recurrent or metastatic thymic carcinoma. In one part, participants receive lucitani…
Phase 2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Elderly cancer patients may benefit from geriatric support
Disease control CompletedThis study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…
Sponsor: Institut Bergonié • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to boost cancer treatment
Disease control CompletedThis early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered donor cells take aim at returning blood cancers
Disease control CompletedThis early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
Disease control CompletedResearchers are testing a combination of L-DEP chemotherapy (aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) and a PD-1 antibody as initial treatment for people with Epstein-Barr virus-positive lymphoma-associated hemophagocytic lymphohistiocytosis, a rare an…
Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Antibody-Guided chemotherapy aims to give relapsed leukemia patients a second shot
Disease control CompletedAdults with B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment have few options. This phase 2 trial tests whether adding epratuzumab, an antibody that attaches to the CD22 protein found on most of these leukemia cells, to standard chemothera…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Which drug cocktail best primes myeloma for transplant?
Disease control CompletedResearchers compare two three-drug combinations, VTD and VCD, as initial treatment for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Participants receive four cycles of either combination. The trial measures how well each combination re…
Phase 3 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can an Anti-Inflammation drug make AML chemotherapy work better?
Disease control CompletedResearchers are testing whether adding tocilizumab, a drug that blocks an inflammation signal called IL-6, to standard chemotherapy helps adults with high-risk acute myeloid leukemia. Participants receive idarubicin and cytarabine, the usual induction chemotherapy, plus a single …
Phase 1 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triple drug combo targets mantle cell lymphoma
Disease control CompletedResearchers are testing a combination of three drugs, obinutuzumab, ibrutinib, and GDC-0199, in people with mantle cell lymphoma. The trial includes patients whose cancer has come back or stopped responding to treatment, as well as those who have not yet received treatment. The g…
Phase 1/2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new drug combo improve myeloma treatment for older adults?
Disease control CompletedResearchers are testing a combination of carfilzomib, melphalan, and prednisone in adults over 65 with newly diagnosed multiple myeloma. The trial first aims to find the highest dose of carfilzomib that people can tolerate without severe side effects. Then it will measure how wel…
Phase 1/2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triplet therapy aims to deepen myeloma remission around transplant
Disease control CompletedResearchers are testing whether adding the experimental drug MLN9708 to lenalidomide and dexamethasone can help adults under 66 with newly diagnosed multiple myeloma. Participants receive three cycles of the triplet, then a stem cell transplant, followed by more triplet and maint…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Dietary change may curb recurrent c. diff in cancer patients
Disease control CompletedThis study tested whether eating less fat and more fiber can reduce the chance of a repeat Clostridioides difficile infection in cancer patients. Eight participants with leukemia, lymphoma, or other cancers followed a specific diet. Researchers tracked diarrhea and measured C. di…
Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a liposomal chemo combo improve outcomes before stem cell transplant?
Disease control CompletedResearchers are testing whether a liposomal chemotherapy drug called CPX-351 works better than standard chemotherapy before an allogeneic stem cell transplant in adults with higher-risk myelodysplastic syndromes (MDS) or oligoblastic acute myeloid leukemia (AML). The trial enroll…
Phase 2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase 1/2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Spinal cages built to fuse bone: can they steady a slipping spine?
Disease control CompletedResearchers are studying a spinal implant called the EVOS Lumbar Interbody System, which uses PEEK-OPTIMA HA enhanced cages, in adults with degenerative disc disease or grade 1 spondylolisthesis in the lower back. The study follows participants who receive the device during spina…
Sponsor: Invibio Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Two-Drug combo aims to push CLL into deep remission
Disease control CompletedResearchers are testing whether combining ibrutinib and venetoclax can help people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial assigns participants to either a fixed course of the two drugs or a course guided by a sensitive test…
Phase 2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for rare skin cancer: targeted antibody tested in china
Disease control CompletedThis study tests a drug called mogamulizumab in 23 Chinese adults with mycosis fungoides or Sézary syndrome, two types of skin lymphoma that have not responded to previous treatments. The drug is given as an IV infusion and aims to shrink or eliminate cancer in the skin, lymph no…
Phase 4 • Sponsor: Kyowa Kirin China Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Radioactive antibody vs stem cell transplant: which keeps lymphoma at bay?
Disease control CompletedThis phase III trial compares two consolidation treatments for people with relapsed or refractory follicular lymphoma whose cancer has shrunk after chemotherapy. Participants receive either a radioactive antibody called Zevalin or high-dose chemotherapy followed by an autologous …
Phase 3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a common nerve pain drug restore brain chemistry in bipolar cannabis users?
Disease control CompletedThis study tests whether gabapentin, an FDA-approved medication, can help restore the balance of key brain chemicals (GABA and glutamate) in people with bipolar disorder who also use cannabis. Participants are randomly assigned to receive either gabapentin or a placebo for 17 day…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a shorter drug combo improve outcomes for older AML patients?
Disease control CompletedResearchers are testing whether a combination of venetoclax and a three-day course of decitabine works better than the standard pairing of venetoclax and azacitidine for older or unfit adults newly diagnosed with acute myeloid leukemia. The trial enrolls 154 participants and comp…
Phase 3 • Sponsor: The Second Affiliated Hospital of Kunming Medical University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New vaccine aims to shield leukemia patients from COVID-19
Disease control CompletedThis phase 2 trial tests a new COVID-19 booster vaccine (GEO-CM04S1) in 80 people with chronic lymphocytic leukemia (CLL). The goal is to see if this vaccine triggers a stronger immune response than standard mRNA boosters. Participants will receive either the new vaccine or a sta…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can cutting arginine from the diet starve solid tumors?
Disease control CompletedThis phase 1 trial is testing whether a diet that severely limits arginine—an amino acid some tumors depend on—is safe and might help control solid tumors. About 25 adults with solid tumors will follow a specially designed low-arginine liquid diet for two 3-week cycles while cont…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could flickering lights and tones help fight Alzheimer's? major trial underway
Disease control CompletedThis study tests a device that delivers specific light and sound patterns to the brain, aiming to slow the progression of mild-to-moderate Alzheimer's disease. About 670 participants will use the device at home for an hour daily over a year, with half receiving a sham (inactive) …
Sponsor: Cognito Therapeutics, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat leukemia in younger patients
Disease control CompletedThis study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blo…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase 1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Pairing a steroid with lymphoma gel may prevent painful skin reactions
Disease control CompletedThis phase 2 trial tests whether adding triamcinolone 0.1% ointment to Valchlor gel reduces contact dermatitis, a common skin reaction, in people with early-stage cutaneous T-cell lymphoma. Participants apply Valchlor nightly, with or without the steroid up to three times daily, …
Phase 2 • Sponsor: Rochester Skin Lymphoma Medical Group, PLLC • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Old drug, new hope: enasidenib may ease anemia in blood cancer patients
Disease control CompletedThis early-phase trial tested the drug enasidenib in 17 people with low-risk myelodysplastic syndrome or a related leukemia who had anemia and did not have a specific gene mutation. The goal was to see if the drug could safely improve red blood cell counts and reduce the need for…
Phase 1/2 • Sponsor: Tian Yi Zhang • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new pill boost Immunotherapy's power against advanced tumors?
Disease control CompletedThis trial tests an experimental drug called FLX475, given alone or with the immunotherapy pembrolizumab, in people with advanced cancers that have not responded to standard treatments. The study aims to find the safest dose and to see whether the combination can shrink tumors. P…
Phase 1/2 • Sponsor: RAPT Therapeutics, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Which lymphoma drug combo works best? a new study aims to find out
Disease control CompletedThis study looks at how well different immunochemotherapy combinations, such as RCHOP, BR, and RCVP, work for people with small B-cell non-Hodgkin lymphoma. Researchers will track 206 adults with this type of lymphoma to see how many respond to treatment and how long they stay fr…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Fiber fuel: could a High-Fiber diet boost cancer treatment?
Disease control CompletedThis study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart returning leukemia?
Disease control CompletedThis trial tests whether adding venetoclax to a standard chemotherapy pair (cytarabine and mitoxantrone) can help adults with acute myeloid leukemia that has relapsed or not responded to initial treatment. In the first phase, researchers find the highest safe dose of cytarabine w…
Phase 1/2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Four-Drug cocktail tackle Hard-to-Treat myeloma spread?
Disease control CompletedThis phase 2 trial tests a combination of four drugs, selinexor, bortezomib, lenalidomide, and dexamethasone (SVRd), in people newly diagnosed with multiple myeloma whose disease has spread outside the bone marrow, called extramedullary disease. The study aims to see how well thi…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new antibody help the immune system fight Hard-to-Treat tumors?
Disease control CompletedThis trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…
Phase 1/2 • Sponsor: Sensei Biotherapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Experimental T-Cell therapy takes aim at lymphoma
Disease control CompletedThis early-phase trial tests a new therapy for Hodgkin and non-Hodgkin lymphoma that has returned or not responded to standard treatment. Researchers take a patient's own immune cells, train them in the lab to recognize five cancer-specific proteins (tumor-associated antigens), a…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo drug shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThis phase 2 trial tests a new drug combination called MK-4280A (favezelimab plus pembrolizumab) against standard chemotherapy in people with classical Hodgkin lymphoma that has come back or stopped responding to treatment. About 200 participants will be randomly assigned to rece…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New daily pill shows promise in controlling leukemia
Disease control CompletedThis study tested a daily medication called acalabrutinib in 552 adults with chronic lymphocytic leukemia (CLL), a type of blood cancer. Participants included those newly diagnosed, those whose cancer returned, and those who had previously taken a similar drug. The goal was to se…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can an experimental drug shrink advanced solid tumors?
Disease control CompletedThis phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new drug pair tame hodgkin lymphoma in older patients?
Disease control CompletedThis trial tests whether combining two drugs, brentuximab vedotin (Adcetris) and bendamustine (Levact), can safely and effectively treat Hodgkin lymphoma in people aged 60 to 80 who have not had prior treatment. The standard therapy, ABVD, often causes lung damage in older adults…
Phase 1/2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New 4-Drug cocktail aims to crush myeloma early
Disease control CompletedThis phase 2 study tested a sequence of four drugs—carfilzomib, clarithromycin, lenalidomide, and dexamethasone—in 74 people newly diagnosed with multiple myeloma. The goal was to see how safe and effective this combination is at controlling the disease. Participants first receiv…
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a targeted drug combo outsmart brain lymphoma?
Disease control CompletedThis early-stage trial is testing whether adding the targeted drug orelabrutinib to a standard chemotherapy regimen can safely treat newly diagnosed primary central nervous system lymphoma (PCNSL), a rare type of lymphoma that starts in the brain or spinal cord. The study will en…
Phase 1 • Sponsor: Huashan Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug combo shows promise for rare blood cancer in early trial
Disease control CompletedThis study tests adding the drug romidepsin to standard chemotherapy (CHOEP) for young adults (ages 18-65) with a rare type of lymphoma called peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before patients undergo a stem cell transplant. …
Phase 1/2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Engineered immune cells show promise against tough lymphoma
Disease control CompletedThis phase 2 study tested a personalized cell therapy called KTE-X19 (brexucabtagene autoleucel) in 95 adults with mantle cell lymphoma that had returned or stopped responding to prior treatments. Participants received a single infusion of their own genetically modified immune ce…
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a new drug erase the last traces of leukemia?
Disease control CompletedThis phase 2 trial is testing whether adding venetoclax, a pill taken daily for 12 months, can reduce the number of leukemia stem cells that remain in the bone marrow of people with chronic myeloid leukemia (CML) who are already in deep molecular remission on standard TKI therapy…
Phase 2 • Sponsor: Thomas Ernst, PD Dr. med. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a pill keep blood cancer at bay after a stem cell transplant?
Disease control CompletedThis phase III trial is testing whether taking oral azacitidine as a maintenance therapy after an allogeneic stem cell transplant can help prevent relapse in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Participants are randomly assigned to receive…
Phase 3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo shows promise for tough hodgkin lymphoma cases
Disease control CompletedThis study tested a new combination of drugs for people with Hodgkin lymphoma that either returned after treatment or didn't respond. The goal was to find the safest dose of a targeted drug (brentuximab vedotin) when added to standard chemotherapy. 45 adults took part, and the st…
Phase 1/2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Leukemia drug holiday: study tests if patients can pause nilotinib
Disease control CompletedThis study looked at whether people with chronic myeloid leukemia (CML) who have done very well on the drug nilotinib can safely stop taking it. 215 patients who had been on nilotinib for at least two years and had very low levels of cancer cells were enrolled. The main goal was …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Leukemia drug holiday: can patients stop nilotinib and stay Cancer-Free?
Disease control CompletedThis study looked at whether people with chronic myeloid leukemia (CML) who had very low levels of cancer cells could safely stop taking the drug nilotinib (Tasigna). Participants had already been treated with imatinib (Gleevec) and then nilotinib for at least 3 years. The main g…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
Disease control CompletedThis phase III trial is testing whether adding selinexor to a standard two-drug regimen (bortezomib and dexamethasone) can help people with relapsed or refractory multiple myeloma—a blood cancer that has returned or stopped responding to treatment. About 154 adults with measurabl…
Phase 3 • Sponsor: Antengene Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can Lab-Grown stem cells supercharge blood recovery after transplant?
Disease control CompletedThis trial tests whether stem cells grown in the lab before being returned to the body can help blood counts recover faster after a stem cell transplant for multiple myeloma. Adults aged 18 to 65 with myeloma in first response will receive their own amplified stem cells. The main…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can engineered immune cells outsmart transplant-related cancer?
Disease control CompletedThis early-phase trial tests a new type of immunotherapy for people who develop a rare blood cancer called post-transplant lymphoproliferative disease (PTLD) after a solid organ transplant. The treatment uses the patient's own immune cells (T-cells) that are engineered to resist …
Early phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a shorter TB regimen transform child care?
Disease control CompletedThis study looks at how a shorter tuberculosis (TB) treatment regimen works for children and adolescents with non-severe TB in Zambia. It involves children, caregivers, health workers, and policymakers to understand how well the regimen is accepted, followed, and feasible in real…
Sponsor: Centre for Infectious Disease Research in Zambia • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill targets tough cancers in early human trial
Disease control CompletedThis early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…
Phase 1/2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Leukemia drug holiday: study finds many can stop imatinib without relapse
Disease control CompletedThis study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a targeted drug boost standard chemo for an aggressive lymphoma?
Disease control CompletedThis phase 2 trial is investigating whether adding the targeted drug copanlisib to the standard R-CHOP chemoimmunotherapy regimen can help people with previously untreated diffuse large B-cell lymphoma (DLBCL) live longer without their cancer progressing. The study enrolls adults…
Phase 2 • Sponsor: University Hospital Muenster • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a cancer drug's real-world performance match clinical trial results?
Disease control CompletedThis study tracks adults with relapsed or refractory multiple myeloma who are already receiving isatuximab as part of their routine care. Researchers will measure how many patients respond to treatment, how long the response lasts, and how the drug affects quality of life and sid…
Sponsor: Sanofi • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase 1/2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a pill tame a common blood cancer in the real world?
Disease control CompletedThis study follows about 269 people with chronic lymphocytic leukemia (CLL) who are starting venetoclax, a targeted pill. Researchers will track how well the drug shrinks or controls the cancer over the first year, and how long it takes before patients need another treatment. The…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo attack on returning prostate cancer shows promise
Disease control CompletedThis phase 2 trial is testing whether surgery and radiation can help men whose prostate cancer has come back and spread to a few spots in the body. About 20 participants will receive either surgery to remove the spread tumors or targeted radiation, or both. The main goal is to se…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Gentler transplant shows promise for kids with blood diseases
Disease control CompletedThis study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer si…
Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Leukemia drug cocktail aims to boost remission in High-Risk patients
Disease control CompletedThis study tests whether adding the targeted drug venetoclax to standard chemotherapy helps more adults with acute myeloid leukemia (AML) achieve remission. It enrolls people aged 18 to 65 with intermediate- or high-risk AML who have not yet been treated. The main goal is to see …
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Real-World check: does bosutinib control CML safely?
Disease control CompletedThis study tracks the safety and effectiveness of bosutinib (Bosulif) in people with chronic myelogenous leukemia (CML) who are either newly diagnosed or have not responded to or tolerated prior treatments. Researchers will monitor side effects and how well the drug controls the …
Sponsor: Pfizer • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Blood cancer drug shows promise in Long-Term study
Disease control CompletedThis study follows 36 Italian patients with Polycythemia Vera who responded well to Ropeginterferon alfa-2b in an earlier trial. Researchers will check every 6 months whether the treatment continues to keep their red blood cell levels normal and prevent the disease from getting w…
Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New pill takes on tough cancers: first human trial begins
Disease control CompletedThis early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…
Phase 1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Drug cocktail aims to tame advanced leukemia
Disease control CompletedThis phase 2 trial is testing whether combining two drugs, ponatinib and 5-azacitidine, can improve survival in people with advanced chronic myeloid leukemia (CML). The study includes adults whose CML has progressed to an accelerated phase or a more aggressive blast crisis. Parti…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalized dasatinib dosing aims to tame leukemia with fewer side effects
Disease control CompletedThis study tests whether adjusting the daily dose of the leukemia drug dasatinib based on a patient's blood levels can improve safety and effectiveness. Adults newly diagnosed with chronic phase chronic myeloid leukemia (CML) will receive either standard dosing or a dose tailored…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Diabetes drug could help eradicate hidden leukemia cells
Disease control CompletedThis phase 2 trial tests whether adding pioglitazone (a diabetes drug) to the standard leukemia medication imatinib can eliminate remaining cancer cells in people with chronic-phase chronic myeloid leukemia (CML). Participants must have been on imatinib for at least two years and…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug combo aims to outsmart aggressive leukemia
Disease control CompletedThis trial tests whether adding the targeted drug ponatinib to standard chemotherapy (cytarabine) can help prevent relapse in adults with a specific, high-risk genetic form of acute myeloid leukemia (FLT3-ITD AML) who are already in first remission. The study includes two age gro…
Phase 1/2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Personalizing leukemia drug doses could boost treatment success
Disease control CompletedThis trial investigates whether adjusting the dose of imatinib (Gleevec) based on the drug's level in the blood can improve outcomes for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). Participants whose imatinib blood level is low after 28 days are rand…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
HIV-Fighting cells show promise in lymphoma treatment
Disease control CompletedThis study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…
Phase 2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Home infusion for myeloma drug passes early safety check
Disease control CompletedThis pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…
Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Could a pill keep AML at bay? new study tests maintenance therapy after chemo
Disease control CompletedThis study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo aims to wipe out hidden myeloma cells after transplant
Disease control CompletedThis phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide maintenance therapy can clear remaining cancer cells in people with multiple myeloma who still have minimal residual disease after a stem cell transplant. About 200 participant…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo aims to tackle tough lymphoma
Disease control CompletedThis study tested whether adding ixazomib to the standard drug ibrutinib can help people with mantle cell lymphoma that has returned or not responded to prior treatment. Forty-three adults received both pills by mouth in cycles. Researchers looked for the best dose and measured h…
Phase 1/2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail shows promise for Tough-to-Treat leukemia in seniors
Disease control CompletedThis study tested a chemotherapy drug called CPX-351 in 59 adults aged 60 to 75 with a high-risk form of acute myeloid leukemia (AML). The goal was to see how well it could put the cancer into remission. Participants received the drug through an IV, and some also had a stem cell …
Phase 2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis study tested a combination of two drugs, brentuximab vedotin and bendamustine, in 65 patients with Hodgkin lymphoma or anaplastic large cell lymphoma that had come back or didn't respond to earlier treatments. The goal was to find the safest dose and see how well the drugs w…
Phase 1/2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted therapy combo aims to improve survival in older leukemia patients
Disease control CompletedThis study tests whether adding the targeted drug inotuzumab ozogamicin to a milder chemotherapy regimen improves survival in adults over 55 with a specific type of acute lymphoblastic leukemia (ALL) that is Philadelphia chromosome-negative and CD22-positive. Participants receive…
Phase 2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma in major trial
Disease control CompletedThis phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…
Phase 3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo shows promise for Tough-to-Treat blood cancer
Disease control CompletedThis study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase 1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may shield cancer Patients' hearts from chemo damage
Disease control CompletedThis study looked at whether using a blood test (NTproBNP) to guide heart-protecting medications can safely prevent heart damage in people with breast cancer or lymphoma receiving anthracycline chemotherapy. About 108 adults participated, and researchers measured how many joined,…
Phase 1/2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Real-World data suggests asciminib may help some leukemia patients
Disease control CompletedThis study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within th…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New hope for elderly lymphoma patients: a gentler treatment that preserves independence
Disease control CompletedThis phase 2 trial investigates whether combining rituximab with lenalidomide works as well as standard rituximab-based chemotherapy for patients aged 75 and older with relapsed diffuse large B-cell lymphoma. The study focuses not only on controlling the cancer but also on mainta…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New oxygen test could cut unnecessary blood transfusions after heart surgery
Disease control CompletedThis study tested whether measuring oxygen levels in the blood (ScvO2) can help doctors decide when to give blood transfusions to anemic patients after heart surgery. 100 patients were randomly assigned to receive transfusions based on standard guidelines or only if their ScvO2 w…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
Disease control CompletedThis phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…
Phase 2 • Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Phase 3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR-T therapy takes on standard care in lymphoma battle
Disease control CompletedThis Phase 3 trial tested whether the CAR-T cell therapy tisagenlecleucel works better than standard treatments for adults with aggressive B-cell non-Hodgkin lymphoma that came back or didn't respond to initial therapy. The study enrolled 330 participants and compared how long th…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for leukemia patients: asciminib shows promise in indian study
Disease control CompletedThis study looked at the safety and effectiveness of a drug called asciminib in 85 Indian adults with a specific type of leukemia (Ph+ CML-CP). Some participants had a genetic mutation (T315I) that can make treatment harder, while others had already tried two or more other drugs.…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Engineered immune cells target tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new treatment for children and young adults with a type of leukemia that came back or did not respond to standard therapy. The approach uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein c…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New chemo cocktail shows promise in myeloma stem cell transplants
Disease control CompletedThis phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage study tested two experimental drugs, odronextamab and cemiplimab, in 105 patients with aggressive B-cell lymphoma that had stopped responding to other treatments. The main goal was to check safety and find the best dose. Researchers also looked at how well the dr…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
One cord blood unit may replace two in stem cell transplants for blood cancer
Disease control CompletedThis study tested a new way to treat blood cancers like leukemia in 16 adults who did not have a standard bone marrow donor. Doctors used a single unit of cord blood that was grown in a lab to increase the number of stem cells before transplant. The goal was to see if this method…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Real-World study confirms Mogamulizumab's effectiveness against rare skin cancer
Disease control CompletedThis study looked at 100 adults with cutaneous T-cell lymphoma (a rare type of skin cancer) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measur…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Protein and exercise combo tested to fight muscle loss in sick kids
Disease control CompletedThis pilot study tested whether giving critically ill children on breathing machines extra protein along with a personalized exercise program could help preserve muscle mass and improve recovery. The trial enrolled 18 children in the ICU and measured how feasible and safe the app…
Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo shows promise for High-Risk leukemia patients
Disease control CompletedThis study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemothera…
Phase 3 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New chemo cocktail aims to beat back leukemia relapse
Disease control CompletedThis phase 2 trial tests whether a combination of clofarabine and intermediate-dose cytarabine (CLARA) works better than high-dose cytarabine (HDAC) alone as consolidation therapy for younger adults (18-60) with newly diagnosed acute myeloid leukemia (AML). After initial remissio…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a second-line drug help CML patients stay cancer-free without daily pills?
Disease control CompletedThis study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Real-World data shows Tirabrutinib's promise for rare brain cancer
Disease control CompletedThis study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see…
Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody shows promise in slowing early myeloma
Disease control CompletedThis phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…
Phase 2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Old drug, new hope for rare skin cancer?
Disease control CompletedThis study tested the drug lenalidomide (Revlimid) in 19 people with a rare type of skin lymphoma called leg-type large B-cell lymphoma that had come back or not responded to initial chemotherapy. Participants took lenalidomide pills daily for 21 days, then rested for 7 days, rep…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase 1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Last hope? new combo targets myeloma that resists standard drugs
Disease control CompletedThis phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New transplant strategy shows promise for blood cancer relapse
Disease control CompletedThis study tested a stem cell transplant approach for adults with relapsed follicular lymphoma, a type of blood cancer. The treatment included the drug rituximab to help control the disease and prevent complications. The goal was to see if this strategy could improve survival and…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New lymphoma combo shows promise in major trial
Disease control CompletedThis large Phase 3 trial tested whether adding polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the usual treatment (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants received either the new combo or the standard regime…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Pill may replace shots for blood cancer patients, study finds
Disease control CompletedThis study tested whether an oral medication (CC-486) could help elderly patients with a serious blood disorder called myelodysplastic syndrome (MDS) maintain their improvement after initial injectable treatment. Eleven patients who had responded to injectable azacitidine switche…
Phase 2 • Sponsor: University of Florence • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immune combo shows promise against stubborn lymphoma
Disease control CompletedThis study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shr…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New study checks bleeding risk when CLL drug meets blood thinners
Disease control CompletedThis study observed 45 people with chronic lymphocytic leukemia (CLL) who were taking the drug acalabrutinib (Calquence) along with a direct oral anticoagulant (DOAC), a type of blood thinner. The main goal was to see how many patients had serious bleeding events while on this co…
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug duo shows promise for rare blood cancer
Disease control CompletedThis completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. …
Phase 2 • Sponsor: Won Seog Kim • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New antibody shows promise for rare blood cancers
Disease control CompletedThis phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug is an antibody that targets a protein on cancer cells. It was given alone or with chemotherapy to see if it could shr…
Phase 2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo offers hope for aggressive lymphoma in diverse patients
Disease control CompletedThis study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for kids with hard-to-treat leukemia: experimental combo shows promise
Disease control CompletedThis study tested a new combination of chemotherapy drugs for children and young adults with acute lymphoblastic leukemia (ALL) that had returned or not responded to first treatment. The goal was to find the safest dose of clofarabine when given with other medicines. Twenty parti…
Phase 1 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a cancer drug fix an irregular heartbeat?
Disease control CompletedThis study looked at whether Vidaza, a drug used for acute leukemia, could also help treat atrial fibrillation (an irregular heartbeat). The idea was that Vidaza might reverse certain DNA changes that lower the activity of a gene important for heart function. Only one person took…
Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immune booster after transplant shows promise for blood cancer patients
Disease control CompletedThis early-phase study tested whether giving specially selected donor immune cells (NK cells) soon after a stem cell transplant is safe for people with blood cancers. Seventeen patients received the cells, and researchers monitored for serious side effects within 30 days. The goa…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to shrink lymphoma with less radiation
Disease control CompletedThis study tested a new approach for people with early-stage follicular lymphoma, a slow-growing blood cancer. Instead of standard full-dose radiation, participants received low-dose radiation combined with the drug Obinutuzumab (Gazyvaro). The goal was to see if this combination…
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug cocktails show promise for multiple myeloma patients
Disease control CompletedThis study tested different combinations of cancer drugs (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) in 477 adults newly diagnosed with multiple myeloma who were eligible for a stem cell transplant. The goal was to see which combination worked best before and…
Phase 2 • Sponsor: Mario Boccadoro • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal wa…
Phase 1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail may boost stem cell transplant success in blood cancer
Disease control CompletedThis study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combo. The main goal was to see if…
Phase 2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail aims to crush myeloma early
Disease control CompletedThis phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could le…
Phase 2 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug combo aims to prevent leukemia return after remission
Disease control CompletedThis study tested whether a combination of two drugs, venetoclax and azacitidine, can help adults with acute myeloid leukemia (AML) stay in remission after initial chemotherapy. The goal was to find the right dose and see if it safely delays the cancer from coming back. The study…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Promising combo tackles aggressive lymphoma in large trial
Disease control CompletedThis Phase 3 trial tested whether adding tucidinostat (an oral HDAC inhibitor) to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed MYC/BCL2 double-expressor diffuse large B-cell lymphoma, an aggressive subtype. The study enrolled 423 adults who had n…
Phase 3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Engineered immune cells take on childhood leukemia and lymphoma in landmark trial
Disease control CompletedThis study tested a treatment called KTE-X19, a type of CAR T-cell therapy, in 95 children and adolescents whose B-cell acute lymphoblastic leukemia (ALL) or B-cell non-Hodgkin lymphoma (NHL) had returned or stopped responding to standard treatments. The therapy involves collecti…
Phase 1/2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a new drug combo boost transplant success in lymphoma?
Disease control CompletedThis study tested adding lenalidomide (Revlimid) to standard chemotherapy (RICE) for people with relapsed diffuse large B-cell lymphoma. The goal was to see if the combination is safe and can improve response rates, helping more patients qualify for a stem cell transplant. Only 1…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for lymphoma patients who Can't handle standard chemo
Disease control CompletedThis study tested two different drug combinations for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who cannot take the usual strong chemotherapy. The trial compared a newer drug (inotuzumab ozogamicin) plus standard therapy against another commo…
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Stem cell transplant vs. drugs: which works better for younger myeloma patients?
Disease control CompletedThis study looked at 700 adults up to age 65 with multiple myeloma to see if high-dose therapy with a stem cell transplant works better than standard drug therapy (lenalidomide, bortezomib, and dexamethasone). The goal was to find out which approach delays the cancer from growing…
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Weekly carfilzomib combo shows promise for elderly myeloma patients
Disease control CompletedThis phase 2 study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma. The goal was to find the safest effective dose and see how we…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can lenalidomide keep myeloma at bay after transplant?
Disease control CompletedThis phase 3 trial tested whether taking lenalidomide (Revlimid) after an autologous stem cell transplant helps people with myeloma stay in remission longer. Over 600 participants under age 65 who had no signs of progression after transplant were randomly assigned to receive lena…
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for hard-to-treat myeloma patients?
Disease control CompletedThis study tested a drug called daratumumab combined with dexamethasone in 64 people with multiple myeloma that had stopped responding to three other treatments. The goal was to see how many patients' tumors shrank or disappeared. The treatment is not a cure, but aims to control …
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New cocktail aims to tackle tough myeloma cases
Disease control CompletedThis study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Stem cell hope for leukemia patients
Disease control CompletedThis study looked at whether a stem cell transplant can help people under 65 with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. 241 participants received either standard treatment or a transplant. The main goal was to see how long th…
Phase 3 • Sponsor: University Hospital, Caen • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can a drug combo overcome resistance in multiple myeloma?
Disease control CompletedThis study tested whether adding a drug called vorinostat to the standard combination of lenalidomide and dexamethasone could help patients whose multiple myeloma had stopped responding to lenalidomide. The trial enrolled 25 adults with relapsed or refractory multiple myeloma. Th…
Phase 1/2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New cocktail aims to wipe out CLL early
Disease control CompletedThis phase 2 trial tested a combination of chemotherapy (FCR) plus the drug lenalidomide in 21 people with previously untreated chronic lymphocytic leukemia (CLL). The goal was to see if adding lenalidomide could help more patients achieve a complete response, meaning no signs of…
Phase 2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Bone drug shows promise for rare mast cell disorder
Disease control CompletedThis study tested whether denosumab, a drug given as a shot every 6 months, can improve bone density in people with osteoporosis caused by systemic mastocytosis. 24 adults with the condition took part. The goal was to see if the drug strengthens bones and prevents fractures bette…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Coaching lowers blood pressure in kidney patients
Disease control CompletedThis study tested whether an educational worksheet plus health coaching could help people with chronic kidney disease improve their blood pressure. 320 adults with moderate to severe kidney disease and uncontrolled high blood pressure took part. The goal was to see if the coachin…
Sponsor: University of Michigan • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy aims to shrink spleens in bone marrow cancer patients
Disease control CompletedThis study tested whether adding the experimental drug navitoclax to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. The main goal was to see if the combination could shrink an enlarged spleen by at le…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can kids with cancer stop antibiotics sooner? new trial investigates
Disease control CompletedThis study looked at whether children with cancer and a fever caused by low white blood cells can safely stop antibiotics earlier than usual. 55 children took part, and half stopped antibiotics once their fever was gone for 48 hours, while the other half continued until their whi…
Phase 4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New lens implant could sharpen vision for kids with cataracts and astigmatism
Disease control CompletedThis study tested a toric intraocular lens implant in 40 children aged 6 to 17 with cataracts and astigmatism (a condition where the eye is shaped like a football). The goal was to see if this special lens could improve vision better than standard surgery. All children had catara…
Sponsor: Kazakh Eye Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New dosing study aims to tame Drug-Resistant leukemia
Disease control CompletedThis study tested three different starting doses (45 mg, 30 mg, and 15 mg daily) of the drug ponatinib in 283 adults with chronic phase chronic myeloid leukemia (CML) that had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to …
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells show promise against tough lymphoma
Disease control CompletedThis phase 2 study tested a single infusion of brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy, in 105 patients with relapsed or refractory mantle cell lymphoma. The treatment aims to help the body's own immune cells recognize and attack cancer. Results showed that many…
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Last-resort leukemia combo shows early promise in tiny trial
Disease control CompletedThis early-phase study tested a combination of two drugs, venetoclax and omacetaxine, in 6 adults with acute myeloid leukemia (AML) whose cancer had stopped responding to venetoclax-based treatments. The main goal was to find the safest dose of omacetaxine when given with venetoc…
Phase 1 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Microtransplant without immune drugs shows promise for leukemia patients too sick for standard transplant
Disease control CompletedThis early-phase trial tested a new type of stem cell transplant called a microtransplant in 25 people with myeloid blood cancers (like leukemia) who were too old or frail for a standard transplant. Unlike a regular transplant, this one used stem cells from a partially matched fa…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase 1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Head-to-Head chemo battle: which regimen works better for hodgkin lymphoma?
Disease control CompletedThis Phase 3 trial tested two chemotherapy combinations—BEGEV and GDP—in 88 adults with relapsed or refractory classical Hodgkin lymphoma. Patients received either regimen in 21-day cycles, and their response was checked with a PET scan after three cycles. Those who achieved at l…
Phase 3 • Sponsor: Cairo University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control CompletedThis study tested a therapy called bb2121, made from a patient's own immune cells that are reprogrammed to attack myeloma cells. It included over 300 people with multiple myeloma that had returned or was high-risk. The goal was to see if the treatment could shrink tumors and cont…
Phase 2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One donor, two transplants: could this end lifelong Anti-Rejection drugs?
Disease control CompletedThis pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas
Disease control CompletedThis early-phase study tested a new type of cell therapy called ALLO-501, made from donor cells rather than the patient's own cells, in 50 adults with lymphoma that had come back or stopped responding to treatment. The therapy targets CD19, a protein on cancer cells, and was give…
Phase 1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Leukemia drug shows promise in french compassionate use study
Disease control CompletedThis study looked at how well blinatumomab works and how safe it is in 92 adults with B-cell acute lymphoblastic leukemia that had come back or was not responding to treatment. Patients received the drug through a French compassionate use program. Researchers measured survival, r…
Sponsor: Group for Research in Adult Acute Lymphoblastic Leukemia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested whether adding zanubrutinib to obinutuzumab works better than obinutuzumab alone for adults with follicular lymphoma that returned or didn't respond to prior treatments. About 217 people took part. The main goal was to see how many patients had their tumors shri…
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo shows promise for rare thymic cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and lenvatinib, in 43 people with advanced thymic carcinoma or a related thymoma that had worsened after standard chemotherapy. The goal was to see if the combination could stop or slow cancer growth. Participants receiv…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Tailored treatment shows promise for slowing early dementia
Disease control CompletedThis study tested whether a personalized treatment plan—based on each person's test results—works better than standard care for people with mild cognitive impairment or early-stage dementia. 73 adults aged 45-76 took part, receiving either the tailored plan or usual care for 9 mo…
Phase 3 • Sponsor: Alzheimer's Prevention and Reversal Project, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Stem cell transplant shows promise against rare blood cancer
Disease control CompletedThis study tested whether a stem cell transplant (using the patient's own cells) works better than standard chemotherapy for people with a high-risk form of Waldenström macroglobulinemia, a rare blood cancer. 70 patients in China took part. The goal was to see if the transplant c…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New oral combo shows promise for rare blood cancer
Disease control CompletedThis study tested a treatment plan using thalidomide, cyclophosphamide, and dexamethasone, followed by long-term thalidomide and prednisone, in 44 adults newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see how well the oral regimen control…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo therapy shows promise for rare blood cancer in younger patients
Disease control CompletedThis study tested two chemotherapy regimens (EDOCH and DHAP) given one after the other, with or without the targeted drug rituximab, in 55 younger adults (65 or under) newly diagnosed with mantle cell lymphoma. The goal was to see which combination better controls the cancer and …
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for rare blood cancer: which drug combo works best?
Disease control CompletedThis study tested two different drug combinations in 35 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see which combination better controls the disease and improves survival without progression. Participants received either rituxi…
Phase 4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a pill mop up hidden leukemia cells after chemo?
Disease control CompletedThis study tested the drug ibrutinib in 35 people with chronic lymphocytic leukemia (CLL) who still had small amounts of cancer cells after their first treatment. The goal was to see if ibrutinib could clear those leftover cells from the blood and bone marrow. Participants took i…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
PET scans could spare hodgkin patients from extra chemo
Disease control CompletedThis study tested whether using an early PET scan after two rounds of chemotherapy can help doctors choose the right treatment for people with advanced Hodgkin lymphoma. Patients whose scan showed a good response got a milder chemo, while those with less response continued strong…
Phase 3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Promising combo slows myeloma progression in Late-Stage trial
Disease control CompletedThis study tested whether adding the drug isatuximab to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to prior treatments. 302 adults who had already received 1 to 3 prior therapies took part…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Light-Activated ointment shows promise for rare skin cancer
Disease control CompletedThis study tested a synthetic ointment (HyBryte) activated by visible light to treat mycosis fungoides, a type of skin lymphoma. Ten adults with early-stage disease received treatment for up to 54 weeks. The goal was to see if the ointment could reduce redness, scaling, and plaqu…
Phase 2 • Sponsor: Ellen Kim, MD • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New dosing strategy for myeloma drug shows promise in early trial
Disease control CompletedThis study tested a new way of giving the drug elranatamab to people with multiple myeloma that came back or didn't respond to treatment. The drug was given as a shot under the skin, starting with low doses and then increasing, with longer breaks between doses over time. The goal…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy aims to improve life quality in AML patients too sick for standard chemo
Disease control CompletedThis study looked at how adults with a specific type of acute myeloid leukemia (AML) who cannot receive standard chemotherapy feel and function while taking a combination of ivosidenib and azacitidine. The main goal was to measure quality of life using questionnaires, along with …
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo shows promise for Tough-to-Treat myeloma
Disease control CompletedThis study tested a combination of pomalidomide and dexamethasone in 63 patients with multiple myeloma that had returned or stopped responding to treatment, and who had specific high-risk genetic changes. The goal was to see how well the drugs controlled the disease and what side…
Phase 2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Promising chemo cocktail shows hope for AML patients under 60
Disease control CompletedThis study tested a three-drug chemotherapy combination (cladribine, homoharringtonine, and cytarabine) in 65 adults under 60 with newly diagnosed acute myeloid leukemia (AML). The goal was to see how well it wiped out leukemia cells and how safe it was. Results tracked complete …
Phase 2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered T-Cells take on blood cancers in early trial
Disease control CompletedThis early-phase study tested a new type of cell therapy for people with advanced B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL) that had returned or not responded to standard treatments. Researchers took patients' own immune cells (T-cells) and added a special…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase 1/2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Phase 1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for myelofibrosis patients: drug combo shows promise in shrinking spleens
Disease control CompletedThis study tested a drug called navitoclax, either alone or added to the standard drug ruxolitinib, in 191 people with myelofibrosis. The main goal was to see if the treatment could shrink the spleen by at least 35% after 24 weeks. The trial also looked at whether it could reduce…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase 1/2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo aims to keep mantle cell lymphoma in check
Disease control CompletedThis phase 2 trial tested whether adding the targeted drug obinutuzumab to standard chemotherapy (DHAP) and stem cell transplant could better control mantle cell lymphoma in 86 previously untreated patients. Participants received obinutuzumab during induction, before transplant, …
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Major trial tests best drug combo for blood cancer control
Disease control CompletedThis study tested different drug combinations in 1,503 adults aged 18-65 with newly diagnosed multiple myeloma. The goal was to see which approach—standard drugs or high-dose chemo with stem cell transplant—works better to delay the cancer's return. Patients received maintenance …
Phase 3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Can a daily antibiotic stop deadly infections in blood cancer patients?
Disease control CompletedThis study tested whether the antibiotic levofloxacin can prevent fevers and infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving the chemotherapy drug azacitidine. Infections are a major risk for these patients. The trial ran…
Phase 3 • Sponsor: Centre Henri Becquerel • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Brushing teeth during aplasia: safe or risky?
Disease control CompletedThis study tested whether brushing teeth is safe for patients with prolonged aplasia (low blood cell counts) after intensive chemotherapy. Currently, many hospitals only allow mouthwash to avoid bleeding and infection. The trial compared brushing with an extra-soft toothbrush plu…
Phase 3 • Sponsor: University Hospital, Angers • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells show promise against stubborn lymphoma
Disease control CompletedThis study tested a one-time treatment using a person's own immune cells, modified to attack cancer, in 159 adults with follicular or marginal zone lymphoma that had returned after at least two prior therapies. The main goal was to see how many patients had their tumors shrink or…
Phase 2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for Hard-to-Treat lymphoma: targeted drug combo shows promise in phase 3 trial
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to standard chemotherapy (R-GEMOX) helps people with relapsed or refractory diffuse large B-cell lymphoma. The study involved 270 participants and compared the combination to chemotherapy alone. The ma…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo therapy shows promise for Hard-to-Treat myeloma
Disease control CompletedThis phase 3 study tested whether adding daratumumab to standard pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma live longer without their disease getting worse. 304 adults who had already tried lenalidomide and a proteasome inhibitor took…
Phase 3 • Sponsor: Stichting European Myeloma Network • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Donor stem cell transplant shows promise for myeloma patients under 65
Disease control CompletedThis study tested whether a stem cell transplant from a matched donor could improve outcomes for myeloma patients under 65 who had already responded well to their own stem cell transplant. Thirteen patients received a reduced-intensity conditioning regimen followed by the donor t…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for myeloma patients Who've run out of options?
Disease control CompletedThis phase 2 trial tested a three-drug combination (ixazomib, cyclophosphamide, and dexamethasone) in 112 patients with multiple myeloma that had returned or stopped responding to three previous treatments. The goal was to see if adding ixazomib to standard chemotherapy could hel…
Phase 2 • Sponsor: University of Leeds • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug combo shows promise for kids with transplant complication
Disease control CompletedThis study tested whether adding the drug ruxolitinib to standard steroids helps children with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. 46 children aged 28 days to 18 years took part. The main goal was to see how many had a complete o…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Real-World study checks how well venetoclax works for AML patients
Disease control CompletedThis study looked at how well the drug Venetoclax works for adults with acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 120 patients in Switzerland and Austria took Venetoclax pills daily as part of their normal care. Researchers tracked …
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Monthly shot may boost opioid treatment success in hospitals
Disease control CompletedThis study tested whether a once-monthly injection of extended-release buprenorphine helps hospitalized patients with moderate to severe opioid use disorder stay in treatment better than usual care (like daily pills or methadone). Over 300 adults were randomly assigned to receive…
Phase 2/3 • Sponsor: Gavin Bart • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
CAR T-Cell therapy shows promise against tough lymphoma in major trial
Disease control CompletedThis phase 3 trial tested whether a personalized cell therapy called axicabtagene ciloleucel (Yescarta) works better than standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 359 participants and compared event-fre…
Phase 3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Chemo-Free combo shows promise for CLL patients
Disease control CompletedThis phase 2 trial tested a chemotherapy-free combination of two drugs, obinutuzumab and ibrutinib, in 135 people with previously untreated chronic lymphocytic leukemia (CLL). The treatment was given for nine months, and then the next steps were decided based on how much leukemia…
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Chemo-Free hope: new combo aims to outsmart CLL
Disease control CompletedThis phase 2 trial tested a combination of two targeted drugs, venetoclax and ibrutinib, against standard chemotherapy (FCR) in 120 fit patients with intermediate-risk chronic lymphocytic leukemia (CLL). The goal was to see if the drug combo could achieve deep remission with a fi…
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for rare blood cancer: lenalidomide dose study shows promise
Disease control CompletedThis study tested the drug lenalidomide in 17 people with Waldenstrom macroglobulinemia, a rare blood cancer, that had returned or stopped responding to prior treatments. The main goal was to find the safest dose by monitoring side effects. Researchers also looked at how many pat…
Phase 1/2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for relapsed myeloma: Triple-Drug cocktail under study
Disease control CompletedThis study tested a combination of three drugs—pomalidomide, cyclophosphamide, and dexamethasone—in 100 patients with multiple myeloma that had returned after initial treatment. All patients had previously been part of the IFM/DFCI 2009 trial. The goal was to see how many patient…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Real-world data on two-drug combo for hard-to-treat hodgkin lymphoma
Disease control CompletedThis study looked at 222 adults with Hodgkin lymphoma that had returned or not responded to first treatment. Researchers wanted to see how well the combination of brentuximab vedotin and bendamustine worked in everyday medical practice. They measured how long patients stayed free…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Gene therapy trial targets HIV and lymphoma together
Disease control CompletedThis early-stage study tested a new gene therapy in 2 HIV-positive people with high-risk lymphoma. The therapy involved taking their own stem cells and immune cells, adding a gene to block HIV, and giving them back after chemotherapy. The main goal was to see if the procedure was…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New Blood-Cleansing method boosts transplant success in High-Risk patients
Disease control CompletedThis study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…
Sponsor: Ting YANG • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control CompletedThis early-phase trial tested a combination of three drugs—selinexor, carfilzomib, and dexamethasone—in 52 patients with multiple myeloma that had returned or stopped responding to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope t…
Phase 1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase 1/2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
App helps young cancer survivors shed pounds
Disease control CompletedThis study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for AML patients: Three-Drug cocktail shows promise in phase 2 trial
Disease control CompletedThis study tested whether adding a drug called pevonedistat to the standard two-drug combination (venetoclax and azacitidine) helps adults recently diagnosed with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. About 164 participants received either the…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for kids with tough cancers: experimental combo shows promise
Disease control CompletedThis early-phase study tested a three-drug combination (carfilzomib, cyclophosphamide, and etoposide) in 4 children whose solid tumors or leukemias had come back or didn't respond to standard treatment. The main goal was to find the safest dose and identify side effects. The stud…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could a smarter chemo schedule help kids beat cancer?
Disease control CompletedThis early-phase trial tested a chemotherapy regimen called DA-EPOCH-R in 4 children with certain B-cell cancers (DLBCL, PMBCL, or PTLD). The drugs are given as a continuous infusion over several days, and doses are adjusted based on how the child's body handles them. The goal wa…
Early phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to stall lymphoma without chemo
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug copanlisib to the standard antibody rituximab helps people with relapsed indolent B-cell non-Hodgkin's lymphoma live longer without their cancer getting worse. The study included 458 adults who had already received at lea…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New 'Bispecific' antibody takes aim at Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a drug called odronextamab in 200 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had stopped responding to prior treatments. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to kill …
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo therapy shows promise in leukemia battle
Disease control CompletedThis study tested whether adding a second drug (pegylated interferon) to the standard leukemia medication nilotinib helps people with newly diagnosed chronic myeloid leukemia (CML) achieve a deeper molecular response faster. About 200 adults under 65 with early-stage CML took par…
Phase 3 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Fasting at night may cut cancer risk in people with blood disorder precursors
Disease control CompletedThis study tested whether fasting for at least 14 hours each night could help overweight people with early blood cancer conditions (MGUS, smoldering myeloma) lose weight and possibly lower their cancer risk. Twenty-three participants were randomly assigned to either the fasting p…
Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Blood 'bath' with light may stop transplant complication
Disease control CompletedThis study tested whether a procedure called extracorporeal photophoresis (ECP) could prevent graft-versus-host disease (GVHD) in 158 people receiving stem cell transplants for blood cancers. ECP involves removing white blood cells, treating them with a light-sensitive drug and U…
Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug shows promise for tough hodgkin lymphoma cases
Disease control CompletedThis Phase 2 trial tested the drug tislelizumab in 46 people with classical Hodgkin lymphoma that had come back or was not responding to treatment. The main goal was to see how many participants had their tumors shrink or disappear. Participants received the drug every 3 weeks un…
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New Pill-and-Antibody combo may replace chemo for common lymphoma
Disease control CompletedThis study tested whether a combination of two drugs (rituximab and lenalidomide) works better than standard chemotherapy plus rituximab for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,030 adults with advanced disease who needed treatment took …
Phase 3 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for rare leukemia: aggressive combo therapy shows promise
Disease control CompletedThis phase 2 trial tested a powerful combination of chemotherapy drugs followed by stem cell transplants in 40 patients under 70 with primary plasma cell leukemia, a rare and aggressive blood cancer. The goal was to see if this intensive approach could improve how long patients l…
Phase 2 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 26, 2026 19:17 UTC
-
Double-Dose transplant strategy shows promise for myeloma patients
Disease control CompletedThis study tested a two-step (tandem) stem cell transplant in 148 people with multiple myeloma. Patients received high-dose melphalan chemotherapy, followed by a second transplant with melphalan plus bortezomib (Velcade). The goal was to see if this approach could delay cancer pr…
Phase 3 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 26, 2026 18:29 UTC
-
New drug cocktail shows promise for relapsed myeloma
Disease control CompletedThis phase 2 study tested a combination of three drugs—carfilzomib, pomalidomide, and dexamethasone—in 54 adults whose multiple myeloma had come back after one or two prior treatments. The goal was to see how many patients responded to the therapy. The study is complete, and resu…
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 13:41 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase 1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
Which scan sees hidden myeloma better: PET or MRI?
Diagnosis CompletedResearchers compare PET scans and MRI to see which imaging method detects more myeloma lesions in adults under 65 with newly diagnosed multiple myeloma. Participants receive both scans at diagnosis, after three cycles of chemotherapy, and at the end of treatment. The study also t…
Phase 3 • Sponsor: Nantes University Hospital • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Could a video call replace the Doctor's office for dementia testing?
Diagnosis CompletedThis study is testing whether a set of memory and thinking tests, usually done in person, can be given remotely over a video call. Researchers will compare results from in-person and remote versions to see if they match. If it works, it could make dementia assessments easier for …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
A simple blood draw might reveal hidden eye lymphoma
Diagnosis CompletedThis study tests whether a blood test can help doctors tell apart uveitis caused by lymphoma from other types of uveitis. Uveitis is an eye inflammation that can lead to vision loss, and in some cases it is a sign of a rare eye lymphoma that may spread to the brain. The researche…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
AI reads MRI scans to spot brain tumors without surgery
Diagnosis CompletedThis study tests whether an artificial intelligence system called GliomaAI-Astro23 can identify a specific type of brain tumor (IDH mutant astrocytoma) from routine MRI scans. Researchers are using existing MRI data from 1,372 patients to train and evaluate the AI. If accurate, t…
Sponsor: Deep Learning Institute of Radiological Sciences • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New ultrasound could spot heart trouble before It's too late for chemo patients
Diagnosis CompletedThis study tested whether a special heart ultrasound (2D strain imaging) can detect early signs of heart damage caused by anthracycline chemotherapy in 100 leukemia patients. The goal is to catch problems sooner, so doctors can adjust treatment and reduce the risk of permanent he…
Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:39 UTC
-
New PET tracer shows promise for spotting myeloma bone lesions
Diagnosis CompletedThis study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…
Phase 3 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Blood test may spot deadly transplant complication earlier
Diagnosis CompletedThis completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:28 UTC
-
New imaging agent could sharpen detection of blood cancers
Diagnosis CompletedThis early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells.…
Phase 1 • Sponsor: University Hospital, Caen • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New DNA test could speed up fungal infection diagnosis in cancer patients
Diagnosis CompletedThis study tested a new DNA test called the MycoGenie kit to see how well it can diagnose invasive aspergillosis, a serious fungal infection, in 350 blood cancer patients. The test looks for the fungus's DNA in blood samples and can also detect drug resistance. The goal is to fin…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
Can a drug and donor cells stop leukemia from returning after transplant?
Prevention CompletedResearchers are testing whether giving azacitidine, a chemotherapy drug, together with donor lymphocyte infusions after a stem cell transplant can prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndrome. About 30 patients will receive the combi…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Vitamin a boost before stem cell transplant may shield the gut
Prevention CompletedThis trial tests whether a single high dose of vitamin A, given before a donor stem cell transplant, can prevent gastrointestinal graft-versus-host disease (GVHD), a condition where donor cells attack the gut. Vitamin A deficiency is linked to a higher risk of this complication, …
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase 2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
New antibiotic may replace standard infection prevention in blood cancer patients
Prevention CompletedThis study tested whether fosfomycin, an older antibiotic, works as well as ciprofloxacin for preventing serious infections in people with blood cancers like leukemia or those receiving a stem cell transplant. 177 adults from 11 Spanish hospitals took part. The main goal was to s…
Phase 3 • Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias • Aim: Prevention
Last updated Jun 27, 2026 13:01 UTC
-
New vaccine strategy aims to shield lymphoma patients from deadly infections
Prevention CompletedThis study tested a two-step vaccine approach to prevent pneumococcal infections in 26 adults with diffuse large B-cell lymphoma who were receiving chemotherapy with rituximab. The vaccines, Prevenar and Pneumovax, were given in a prime-boost sequence to boost immune protection. …
Phase 3 • Sponsor: University Hospital, Tours • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
Diabetes drug shows promise in preventing deadly transplant complication
Prevention CompletedThis study tested whether sitagliptin, a diabetes medicine, could prevent acute graft-versus-host disease (GVHD) in 190 adults receiving stem cell transplants from related or unrelated donors. Participants took sitagliptin along with standard GVHD prevention. The main goal was to…
Phase 3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
Could a simple immunization shield cancer patients from severe COVID-19?
Prevention CompletedThis phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment cou…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Jun 27, 2026 08:07 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can AML patients give their own transfusions at home?
Symptom relief CompletedResearchers at Rigshospitalet in Denmark are testing whether adults newly diagnosed with acute myeloid leukemia can safely measure their own blood counts and give themselves blood and platelet transfusions at home. The study trains and certifies 22 participants to use a home bloo…
Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can an AI chatbot lift the spirits of advanced cancer patients?
Symptom relief CompletedThis trial tests whether an AI emotional companion app can improve depression, anxiety, and demoralization in adults with advanced cancer. Participants use a mobile app where a virtual character holds conversations, reads emotional cues, and offers a link to a human hotline if di…
Sponsor: National Yang Ming Chiao Tung University • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Which mouthguard do patients prefer for jaw pain?
Symptom relief CompletedThis study looked at how satisfied people were with three different types of mouthguards (occlusal splints) for jaw joint and muscle pain (TMD). 27 adults who had jaw pain for at least 3 months and had never been treated for it tried one of the splints. The main goal was to see w…
Sponsor: Mansoura University • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Peppermint and lemon scents put to the test against chemo nausea
Symptom relief CompletedThis phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
Virtual reality goggles could ease cancer Patients' procedure fears
Symptom relief CompletedThis study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can talking it out ease PTSD in cancer patients during a pandemic?
Symptom relief CompletedThis study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Could kids have upper limb surgery fully awake? new trial tests the idea
Symptom relief CompletedThis trial tests whether a local anesthetic injection (ropivacaine) can keep children aged 6 to 12 awake and comfortable during upper limb surgery, avoiding general anesthesia. Children watch cartoons on a tablet for distraction while the anesthetic is given. The study aims to se…
Phase 4 • Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Can a fitness tracker and coaching get teens with leukemia moving?
Symptom relief CompletedThis study tested whether a mobile health program—including a Fitbit with movement reminders, coaching sessions, and a WhatsApp peer support group—could help 20 adolescents and young adults with acute lymphoblastic leukemia (ALL) reduce the time they spend sitting or lying down d…
Sponsor: Children's Hospital Los Angeles • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Cartoon calm: animated film may ease Kids' surgery fears
Symptom relief CompletedThis trial investigates whether a double-reading animated film, watched by both children and their parents before surgery, can reduce anxiety in children aged 3 to 7. The film uses avatars to walk the child through their hospital journey, from room to operating room. Researchers …
Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Ancient remedy takes on chemo nerve damage
Symptom relief CompletedThis study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…
Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Fencing fights fatigue: new program aims to keep blood cancer patients moving
Symptom relief CompletedThis study tested whether a fencing-based exercise program is practical for adults with leukemia or lymphoma who are receiving intensive treatment in a hospital. The goal was to reduce physical decline caused by long bed rest. Eighty patients were invited to take part, and resear…
Sponsor: University Hospital, Angers • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
Special PE program shows promise for building muscle in teens with intellectual disability
Symptom relief CompletedThis study tested a 10-week progressive adapted physical education program for 46 adolescents with mild intellectual disability. Half did the special program plus regular school activities, while the other half stuck to their usual curriculum. Researchers measured upper-body stre…
Sponsor: Inonu University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Virtual forests lift mood: VR nature boosts depression treatment
Symptom relief CompletedThis study tested whether adding virtual reality (VR) nature experiences to standard treatment helps adults with mild to moderate depression feel better. 45 participants were split into three groups: one used a high-end VR lab setup, another used a simple self-managed VR, and a c…
Sponsor: Sykehuset Innlandet HF • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New web tool aims to lighten load for dementia caregivers
Symptom relief CompletedThis study tested a web platform designed for people with mild cognitive impairment or mild to moderate dementia and their primary caregivers. The platform offers social networks, activities, and games to improve quality of life and help them stay in the community longer. Researc…
Sponsor: University Hospital, Rouen • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can lotions and gloves soothe cancer therapy's harsh side effects?
Symptom relief CompletedThis study tested a set of dermo-cosmetic products (hand/foot serum, nail strengthener, dissolving oil, and gloves/slippers) in 20 multiple myeloma patients receiving bispecific antibody therapy. The goal was to see if these natural-based products could prevent or reduce skin and…
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Phone calls may boost chemo success in leukemia patients
Symptom relief CompletedThis study tested whether weekly nurse phone calls could help people with chronic lymphocytic leukemia (CLL) stick to their chemotherapy plan and reduce side effects. Sixty patients were split into two groups: one received regular care, and the other also got a weekly call to che…
Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Digital coaching eases cancer treatment struggles
Symptom relief CompletedThis study tested an online educational program for cancer patients receiving chemotherapy. The program included video sessions, peer discussions, and digital materials to help with symptom management and emotional coping. Researchers compared 212 patients who used the program to…
Sponsor: Zagazig University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Phone therapy eases cancer Survivors' distress in rural areas
Symptom relief CompletedThis study tested a stepped-care telehealth program for cancer survivors living in rural areas who experience anxiety, depression, or sleep problems. Participants received either low-intensity check-ins or high-intensity phone therapy with a licensed therapist, depending on sympt…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New lens promises better sight at all distances for cataract patients
Symptom relief CompletedThis study tested a special type of artificial lens (TECNIS Eyhance IOL) in 62 adults aged 45-75 who had cataract surgery. The goal was to see how well the lens helps people see clearly at different distances, from close up to far away. Researchers measured vision at nine distanc…
Sponsor: Democritus University of Thrace • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
New telehealth coaching aims to ease the financial burden of cancer
Symptom relief CompletedThis study tested a telehealth program called CC LinksTele that provides one-on-one coaching to help cancer survivors and their caregivers manage financial and legal issues related to cancer care. 124 adult patients and caregivers from a pediatric cancer clinic took part. The goa…
Sponsor: Jean Edward • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Simple foot bath may ease chemo fatigue in children
Symptom relief CompletedThis study tested whether a nightly warm foot bath can reduce fatigue in children aged 7-12 with lymphoma who are undergoing chemotherapy. Sixty children took a 20-minute foot bath at 38-40°C for 7 days. The goal was to see if this simple, non-drug approach could improve their en…
Sponsor: Koç University • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Can virtual physio help kids with leukemia? small study tests hybrid approach
Symptom relief CompletedThis study tested whether a hybrid (in-person and online) physiotherapy program is feasible for children aged 4-17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which included tailored exercises and games. The goal was to see if families cou…
Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Free blood transfusions help blood cancer patients choose hospice
Symptom relief CompletedThis study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…
Sponsor: Adam Olszewski • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Teens who beat cancer get stronger with simple strength exercises
Symptom relief CompletedThis study looked at whether 16 weeks of strength training can reduce long-term side effects in teens aged 10-19 who finished treatment for leukemia or lymphoma. Participants did either strength exercises with weights or circuit training with bodyweight and equipment. The goal wa…
Sponsor: Aalborg University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Timing of extra care may boost quality of life in myeloma patients
Symptom relief CompletedThis study looked at whether starting supportive care (like meetings with a nurse, psychologist, or dietitian) right after a multiple myeloma diagnosis helps patients feel better compared to waiting 6 months. Twenty patients took part, and researchers measured their quality of li…
Sponsor: Centre Henri Becquerel • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Beauty sessions may ease anxiety for blood cancer patients in isolation
Symptom relief CompletedThis study tested whether aesthetic therapy sessions (like skincare or makeup) could reduce anxiety and improve quality of life for patients with acute leukemia or those who had a stem cell transplant. These patients are isolated in a protected hospital area for at least 28 days.…
Sponsor: University Hospital, Lille • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Pumping iron against cancer: exercise may protect muscle during chemo
Symptom relief CompletedThis study tested whether a supervised resistance training program could help lymphoma patients maintain muscle mass and physical function while undergoing chemotherapy. Forty-two adults with newly diagnosed lymphoma were randomly assigned to either the exercise program or usual …
Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
Itch relief showdown: which drug stops water-induced agony?
Symptom relief CompletedThis study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching triggered by water contact in people with myeloproliferative neoplasms (a type of blood cancer). 63 participants who had persistent itching rated 5 or higher on a 10-poi…
Phase 3 • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Laser or ozone: which eases cancer mouth sores best?
Symptom relief CompletedThis study tested two treatments—laser therapy and ozone gas—to relieve painful mouth sores caused by cancer treatment. Forty adults with head and neck or blood cancers took part. Each received one treatment daily for five days. The goal was to see which therapy better reduced so…
Sponsor: University of Pavia • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Heart rate training boosts exercise benefits for cancer survivors
Symptom relief CompletedThis study looked at whether adding heart rate biofeedback training to regular physical activity can improve quality of life for people who have finished treatment for blood cancers. 80 adults in remission took part. The goal was to see if this combination helps them feel better …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
Brain tumor insomnia targeted by CBT in new pilot study
Symptom relief CompletedThis study tested a type of talk therapy called Cognitive Behavioral Therapy for Insomnia (CBT-I) in 70 people with brain tumors who also had trouble sleeping. The therapy involved six weekly group sessions delivered online. The main goal was to see if the approach was practical …
Phase 2 • Sponsor: Virginia Commonwealth University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
HIIT and weights show promise for stem cell recovery
Symptom relief CompletedThis study looked at whether 12 weeks of high-intensity interval training (HIIT) and resistance training could help people who had a stem cell transplant for blood cancer. It involved 16 patients and their caregivers. The goal was to see if exercise improves physical function, th…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can early palliative care ease suffering in relapsed leukemia?
Symptom relief CompletedThis study looked at whether early, regular visits from a palliative care team can improve quality of life for adults with acute leukemia that has returned. 49 patients were assigned to either receive this extra support or standard care. The team addressed physical, emotional, an…
Sponsor: Hospices Civils de Lyon • Aim: Symptom relief
Last updated Jun 26, 2026 16:57 UTC
-
Empowerment program shows promise for healthier habits in young leukemia patients
Symptom relief CompletedThis study tested a child-centered empowerment program designed to help children with leukemia improve their lifestyle habits, including nutrition, sleep, physical activity, and stress management. Forty-six children aged 7-13 took part, with half receiving the program and half ge…
Sponsor: Near East University, Turkey • Aim: Symptom relief
Last updated Jun 26, 2026 14:44 UTC
-
Can blood markers predict how MS affects walking and thinking?
Knowledge-focused CompletedResearchers are studying whether certain immune substances in the blood are linked to physical and mental abilities in people with relapsing-remitting multiple sclerosis. The study includes 20 adults aged 19 to 45 with mild disability. Participants give blood samples, and researc…
Sponsor: Halic University • Aim: Knowledge-focused
Last updated Sep 21, 2026 19:00 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Dust and crops: scientists hunt for Pesticide-Leukemia link in kids
Knowledge-focused CompletedThis study looked at 629 children in California to see if exposure to pesticides at home or from nearby farms is linked to childhood leukemia. Researchers collected dust from carpets and vacuum cleaners and mapped crops near homes. The goal was to measure chemical levels and see …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Lab tests could pick the right drug for tough myeloma cases
Knowledge-focused CompletedThis study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists decode cancer genes to personalize treatment
Knowledge-focused CompletedThis completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists map protein patterns in lymphoma to unlock disease secrets
Knowledge-focused CompletedThis completed study analyzed leftover tissue samples from 130 people with lymphoma or related conditions. Researchers measured levels of histone and other proteins to find patterns linked to different lymphoma types. The goal was to better understand the biology of these cancers…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Mining Responders' tumors for clues to a universal cancer therapy
Knowledge-focused CompletedResearchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden cancer in kids
Knowledge-focused CompletedThis study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
The immune cells that could make stem cell transplants work better
Knowledge-focused CompletedResearchers are studying natural killer (NK) cells in people who receive stem cell transplants for leukemia. The study follows 92 patients and their donors, looking at genes called KIR and HLA that control how NK cells work. By tracking NK cells during immune recovery, researcher…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Pens and vouchers: can small rewards boost participation in blood cancer research?
Knowledge-focused CompletedResearchers want to learn what causes myeloproliferative neoplasms, a group of rare blood cancers. They are testing whether small incentives like pens, trolley tokens, or a £10 reimbursement encourage more people to join a case-control study. The trial includes about 100 patients…
Sponsor: Queen's University, Belfast • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Leukemia treatment showdown: which works best?
Knowledge-focused CompletedThis registry study follows 400 patients with a specific type of leukemia (non-high-risk APL) who are 70 or younger. It compares two standard treatments: ATRA plus chemotherapy versus ATRA plus arsenic trioxide. The goal is to see which approach leads to better long-term outcomes…
Sponsor: Groupe Francophone des Myelodysplasies • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
PET scans may reveal hidden leukemia spots before CAR t treatment
Knowledge-focused CompletedThis pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Preterm Kids' brains tracked to age 9 in new study
Knowledge-focused CompletedThis study follows children born moderately or late preterm (32-36 weeks) to age 9, measuring their thinking, movement, language, behavior, and growth. Researchers compare these kids to full-term peers to understand long-term effects. The goal is to learn how early development pr…
Sponsor: Noordwest Ziekenhuisgroep • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can we predict lung damage from CAR t-cell therapy?
Knowledge-focused CompletedThis study looks back at the medical records of about 266 adults who received CAR T-cell therapy for blood cancers. The goal is to describe lung complications that happen within 30 days or up to 2 years after treatment. Researchers will also look for patient characteristics that …
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can wearables decode the mystery of fatigue?
Knowledge-focused CompletedResearchers are using wearable sensors and smartphone check-ins to track fatigue as it happens in people with myeloma, long COVID, heart failure, and healthy controls. Participants wear an ECG patch and a wrist sensor that measure heart rate, activity, and posture, and they rate …
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Pee and blood may spare patients painful bone marrow needles
Knowledge-focused CompletedThis study looked at 300 people with Waldenström's macroglobulinemia or a related condition to see if blood or urine tests could detect key genetic mutations as accurately as bone marrow biopsies. The goal is to find a less invasive way to monitor the disease over time. Researche…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Can a 3-Minute video help cancer patients understand radiation better than a Doctor's talk?
Knowledge-focused CompletedThis study tests whether a 3.5-minute educational video shown before a doctor's visit helps cancer patients understand radiation therapy better than standard verbal instructions alone. One hundred patients scheduled for radiation will be randomly assigned to receive either the vi…
Sponsor: Jinnah Postgraduate Medical Centre • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Your Child's genes: a new clue in fighting a rare cancer?
Knowledge-focused CompletedThis study looks at whether natural variations in immune-related genes affect how well children with a rare type of lymphoma (ALCL) respond to treatment. By analyzing blood samples from 185 patients, researchers hope to find genetic markers linked to longer periods without the di…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can tracking severe asthma over time unlock better treatments?
Knowledge-focused CompletedThis research program aims to deepen understanding of severe asthma by closely studying its clinical and biological features over time. Researchers will follow more than a thousand people with asthma, aged 6 and older, measuring lung function and tracking how often severe asthma …
Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can a phone call help cancer survivors get the genetic answers they need?
Knowledge-focused CompletedThis study looked at whether offering genetic counseling by phone or video could help more childhood cancer survivors get genetic testing. About 391 survivors took part, comparing remote counseling to usual care. The goal was to see if remote services increase testing uptake and …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Cancer clot care under the microscope: new study mines data for better treatment insights
Knowledge-focused CompletedThis study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can a closer look at bone complications in multiple myeloma improve rehabilitation?
Knowledge-focused CompletedMultiple myeloma, a common blood cancer, often causes bone lesions that lead to pain, fractures, and other serious events. This study reviews medical records of patients diagnosed between 2019 and 2021 to describe how often these bone complications occur and what rehabilitation s…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Fine-Tuning MRI scanners to sharpen the picture of the brain
Knowledge-focused CompletedThis study uses a research-dedicated 3T MRI scanner to develop and optimize imaging protocols in healthy adults. Researchers aim to reduce image distortions, improve contrast and resolution, and create new sequences for functional MRI. The work will help enable future studies in …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Russian study to monitor Real-World use of acalabrutinib in CLL patients
Knowledge-focused CompletedThis observational study will follow about 90 adults with chronic lymphocytic leukemia (CLL) in Russia who are prescribed acalabrutinib as part of their routine care. Researchers will collect data from medical records to see how long patients stay free of disease progression and …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
New dashboard aims to make leukemia trials more inclusive
Knowledge-focused CompletedThis study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enroll…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
New tool could help spot brain issues in At-Risk newborns earlier
Knowledge-focused CompletedThis study is translating and testing a Turkish version of the Hammersmith Neonatal Neurological Examination (HNNE) for high-risk infants, such as premature babies or those with birth complications. Researchers will check if the exam is reliable and valid for use in Turkey by com…
Sponsor: Kahramanmaras Sutcu Imam University • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Exosomes: the decoy receptors that may sabotage lymphoma treatment
Knowledge-focused CompletedThis study investigates why some aggressive B-cell lymphomas stop responding to immunotherapy. Researchers are looking at tiny particles called exosomes that are released by tumor cells and may act as decoys, soaking up therapeutic antibodies before they can reach the cancer. By …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
No new drug, just data: italian study tracks Real-World myeloma care
Knowledge-focused CompletedThis study is not testing a new treatment. Instead, researchers in Italy are observing how doctors currently treat a tough form of multiple myeloma that no longer responds to three main drug classes. They will collect information from medical records of about 250 patients across …
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Can we predict dangerous blood clots in lymphoma patients? a major study aims to find out
Knowledge-focused CompletedThis study looks at how well existing risk models predict dangerous blood clots in people with diffuse large B-cell lymphoma (DLBCL), a common type of blood cancer. Researchers will review medical records from over 1,500 patients across multiple hospitals to see which factors are…
Sponsor: Fondazione IRCCS San Gerardo dei Tintori • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can genes predict liver damage from childhood cancer drugs?
Knowledge-focused CompletedThis study investigates whether certain genetic differences make children with nephroblastoma (kidney cancer) or acute lymphoblastic leukemia (blood cancer) more likely to develop a serious liver condition called hepatic veno-occlusive disease (VOD) during chemotherapy. Researche…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World study tracks Poteligeo's impact on rare skin cancer symptoms
Knowledge-focused CompletedThis completed observational study followed 73 adults with mycosis fungoides or Sézary syndrome who were starting treatment with Poteligeo. Researchers tracked changes in symptoms like itching, skin pain, and fatigue, as well as quality of life for patients and their caregivers. …
Sponsor: Kyowa Kirin Pharmaceutical Development Ltd • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Gut bacteria may hold key to chemo side effects
Knowledge-focused CompletedThis study looked at how chemotherapy affects the gut microbiome in 40 people with non-Hodgkin's lymphoma. Researchers collected stool samples to analyze changes in gut bacteria after treatment. The goal was to better understand why chemotherapy causes digestive problems like dia…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Stem cell transplant leaves many women with hidden gynecological issues
Knowledge-focused CompletedThis study looked at 51 women who had a stem cell transplant for acute leukemia as adults. Researchers wanted to find out how many had gynecological problems like early menopause, vaginal graft-versus-host disease, or cervical issues two years after transplant. They also checked …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Could a pneumonia drug boost leukemia treatment? small trial explores safety and dosing
Knowledge-focused CompletedThis early-phase trial tested whether adding atovaquone (a drug usually used to prevent pneumonia) to standard chemotherapy is safe and reaches effective levels in the blood. It involved 26 children and young adults (ages 1 month to 21 years) newly diagnosed with acute myeloid le…
Early phase 1 • Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
No treatment, just observation: large study looks at PNH blood cells
Knowledge-focused CompletedThis completed study looked at red and white blood cells in people with a rare blood disorder called PNH who also have bone marrow failure. Over 5,500 participants aged 10 and older with aplastic anemia or related conditions provided blood samples. The goal was simply to learn mo…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can scans and blood predict CAR T-Cell success?
Knowledge-focused CompletedThis pilot study looked at whether special scans (18FDG PET-CT) and blood tests could help predict how well CAR T-cell therapy works for people with hard-to-treat non-Hodgkin's lymphoma. Twenty patients were followed for up to a year after treatment. The goal was to see if these …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study examines artery complications in child liver transplants
Knowledge-focused CompletedThis study looked at 583 children who had liver transplants and later developed narrowing or blockage of the liver artery. Researchers wanted to find out how common these problems are and what treatments work best. The goal is to improve care and outcomes for future patients.
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Could natural immune cells help fight leukemia drug resistance?
Knowledge-focused CompletedThis completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Which drug works better for stem cell collection? study compares zarzio and granocyte
Knowledge-focused CompletedThis completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Hidden danger: why some patients can't shake COVID-19
Knowledge-focused CompletedThis study tracked 204 patients with blood cancers or those on certain immune-suppressing treatments to see how often COVID-19 infection persists for 21 days or more. Researchers also looked for factors that make a long infection more likely. The goal was to better understand who…
Sponsor: Maddalena Giannella • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
New study tracks immune cell function after stem cell transplants to personalize care
Knowledge-focused CompletedThis completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New study reveals how well COVID vaccines protect myeloma patients
Knowledge-focused CompletedThis study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…
Sponsor: ASH Research Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New program aims to break down barriers to cancer trial participation
Knowledge-focused CompletedThis pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
What do patients really think? small study asks multiple myeloma survivors about their treatment journey
Knowledge-focused CompletedThis study interviewed 9 people with multiple myeloma who had received at least 5 different treatments. The goal was to learn about their experiences and what factors are most important to them when deciding on a treatment. No new drugs or therapies were tested; instead, the stud…
Sponsor: The Christie NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New training aims to help doctors catch child abuse earlier
Knowledge-focused CompletedThis study looked at whether a new educational program helps doctors-in-training better recognize and respond to child maltreatment. 84 medical residents from Canadian universities took part. The program was delivered either in a group with a leader or on their own. The goal was …
Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Leukemia Patients' hidden threat: fungal infections under microscope
Knowledge-focused CompletedThis study observed 150 adults with a specific type of leukemia (Ph-negative ALL) to see how many developed serious fungal infections during their first weeks of chemotherapy. Researchers tracked infection rates and deaths linked to these infections. The goal was to better unders…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists probe the hidden types of severe childhood asthma
Knowledge-focused CompletedThis completed study looked at 54 children with severe asthma to better understand the different biological features (endotypes) of the disease. Researchers collected blood, saliva, and nasal samples, along with lung samples from bronchoscopies, to analyze immune cells, metabolis…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for clues to why immunotherapy fails in most patients
Knowledge-focused CompletedThis study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for hidden signs in blood cancers to personalize treatment
Knowledge-focused CompletedThis study collected blood, bone marrow, skin, and cheek cell samples from 650 adults with acute leukemia, myelodysplastic syndromes, or myeloproliferative disorders. Researchers analyzed the samples to find genetic, epigenetic, and drug sensitivity patterns that might predict ho…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Iron deficiency in cancer: a hidden problem exposed
Knowledge-focused CompletedThis study looked at how common iron deficiency is in cancer patients starting chemotherapy. Researchers checked iron levels in 480 adults with solid tumors or lymphoma. The goal was to find out how many patients might benefit from iron injections, without using other drugs like …
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New tool aims to give older leukemia patients a stronger voice in treatment choices
Knowledge-focused CompletedThis pilot study tested a communication tool called UR-GOAL in 15 older adults (age 60+) with newly diagnosed acute myeloid leukemia (AML), along with their caregivers and doctors. The tool helps patients share their preferences and goals, so treatment decisions better match what…
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
New EHR tool aims to boost Heart-Health talks for cancer survivors
Knowledge-focused CompletedThis study tested a tool built into electronic health records that prompts doctors to discuss heart health with cancer survivors during routine visits. Researchers enrolled 645 survivors of breast, prostate, colorectal, endometrial, and lymphoma cancers across 12 clinics. The goa…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Blood test could predict leukemia survival
Knowledge-focused CompletedThis study tests whether measuring two substances in the blood—FLT3L and IL-6—during chemotherapy can help predict survival in people with acute myeloid leukemia (AML). Researchers will track 201 newly diagnosed AML patients across 25 French hospitals. The goal is to confirm that…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Personalized medicine for kids with tough cancers: genetic profiling may point to better treatments
Knowledge-focused CompletedThis study looked at whether analyzing the DNA and RNA of children's relapsed or treatment-resistant tumors can help doctors pick targeted therapies. Researchers profiled tumors from 791 children and adolescents using advanced genetic sequencing. The goal was to see how many pati…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Hospital program helps older blood cancer patients plan future care
Knowledge-focused CompletedThis study tested a program to help older patients (age 60+) with blood cancers plan their future medical care while in the hospital. The program focused on completing advance directives and healthcare proxy forms. Out of 41 participants, the study found that the program was feas…
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Can a video call help blood cancer patients prepare for tough decisions?
Knowledge-focused CompletedThis study tested whether a telehealth program could help older patients (60+) with acute myeloid leukemia or myelodysplastic syndrome discuss and document their future medical wishes. Researchers enrolled 36 patients, caregivers, and clinicians to see if the program was easy to …
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New program aims to ease financial burden for young cancer survivors
Knowledge-focused CompletedThis study tested a program called FinFit to help adolescent and young adult cancer survivors deal with money problems caused by their illness. Researchers interviewed 16 people from community cancer clinics to design and improve the program. The goal was to figure out the best w…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Child cancer and birth defects: hidden genetic clues?
Knowledge-focused CompletedThis completed study collected information from nearly 1,000 children who had both cancer and developmental abnormalities like birth defects or growth issues. The goal was to find new genetic syndromes that make children more likely to develop cancer. Researchers analyzed blood a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
French study tracks Real-World use of oral azacitidine for AML in remission
Knowledge-focused CompletedThis completed study collected real-world data from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. The goal was to describe patient characteristics, treatment patterns, and outcomes like relapse and…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Heart risks during CAR T-Cell therapy under the microscope
Knowledge-focused CompletedThis study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys before and after treatment. The goal was to learn how often heart problems occur a…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Heart iron levels measured in Transfusion-Dependent patients
Knowledge-focused CompletedThis study measured how often iron builds up in the heart muscle of people who receive many blood transfusions. Researchers used MRI scans to check heart iron levels in 110 patients with thalassemia, sickle cell disease, or myelodysplasia. The goal was to understand how common th…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Lockdown diaries: 1,300 patients reveal hidden health risks
Knowledge-focused CompletedThis study looked at how the COVID-19 lockdown changed the health habits and medical care of 1,343 people with chronic conditions like heart disease, multiple sclerosis, and hemophilia. Researchers used phone surveys to track medication use, lifestyle changes, and access to healt…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Parents test new app to track baby eczema and gut health
Knowledge-focused CompletedThis completed study looked at how well parents of infants with early eczema and parents of healthy infants could use a mobile-friendly platform called OneBiome. The platform gives reports on the baby's gut microbiome and eating patterns. Researchers wanted to see if parents foun…
Sponsor: Danone Asia Pacific Holdings Pte, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Major MDS study tracks 2,115 patients to unlock disease secrets
Knowledge-focused CompletedThis completed study enrolled over 2,100 people with or suspected of having myelodysplastic syndromes (MDS), a group of blood disorders. Researchers collected medical data, blood, and tissue samples over time to track how the disease develops and progresses. The goal was to creat…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
HIV Patients' CAR T-Cell cancer treatment under the microscope
Knowledge-focused CompletedThis study looked back at 30 people with HIV who received a special cancer treatment called CAR T-cell therapy for certain blood cancers. Researchers collected information from medical records to see what side effects occurred and how the immune system changed over time. The goal…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Carbon fiber braces could ease ankle strain, early study suggests
Knowledge-focused CompletedThis study tested custom carbon fiber ankle braces in 9 healthy adults to see how they change forces across the ankle joint. Researchers varied the brace design and used a computer model to estimate joint contact stress. The goal was to improve the model and understand how brace …
Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Leukemia Survivors' immunity under the microscope
Knowledge-focused CompletedThis study followed 89 children who finished chemotherapy for acute lymphoblastic leukemia (ALL) to see how their immune systems bounced back. Researchers measured antibody levels for vaccine-preventable diseases and tracked infections during the first year off treatment. The goa…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Gut health under the microscope: new study targets hidden danger in ICU blood cancer patients
Knowledge-focused CompletedThis completed study looked at how common gut inflammation and leaky gut are in 80 adults with blood cancer who were in intensive care for sepsis or septic shock. Researchers measured two markers—calprotectin in stool and zonulin in blood—to better understand intestinal dysfuncti…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Could tiny particles explain clot danger in kids with leukemia?
Knowledge-focused CompletedThis completed study looked at 24 children with acute lymphoblastic leukemia to see if tiny cell fragments called microparticles contribute to dangerous blood clots during treatment. Researchers collected blood samples to measure these particles and a clotting protein on their su…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Needle-Free myeloma monitoring: blood test and MRI show promise
Knowledge-focused CompletedThis study explored whether a simple blood test (liquid biopsy) and a whole-body MRI can detect leftover cancer cells in people with multiple myeloma, potentially replacing the need for a bone marrow biopsy. Researchers enrolled 36 adults with newly diagnosed or previously treate…
Sponsor: Rajshekhar Chakraborty, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Which donor search strategy saves more lives?
Knowledge-focused CompletedThis study looked at 1,753 patients needing a stem cell transplant for blood cancers or other serious blood disorders. Researchers compared two strategies: first searching for a matched unrelated donor, then trying an alternative donor if needed, versus going straight to an alter…
Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Blood mutation may reveal hidden lymphoma after treatment
Knowledge-focused CompletedThis study looked at 137 adults with newly diagnosed classical Hodgkin lymphoma to see if a specific genetic change (XPO1 E571K) found in their blood could signal whether cancer remains after chemotherapy. Researchers compared the blood test results with standard PET scans to mea…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Blood test could replace bone marrow biopsy for rare blood cancer monitoring
Knowledge-focused CompletedThis study looked at 45 adults newly diagnosed with Waldenström's disease, a rare blood cancer. Researchers compared different lab methods to detect a common genetic mutation (MYD88 L265P) in blood and bone marrow samples. The goal was to find less invasive ways to diagnose and t…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Timing tumor DNA tests after chemo: a small study
Knowledge-focused CompletedThis study measured how levels of circulating tumor DNA (ctDNA) change in the hours after the first round of chemotherapy in 24 people with diffuse large B cell lymphoma. The goal was to find the best time to take blood samples for monitoring the cancer. Researchers hope that a b…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Swallow a thermometer? new study tests pill that takes your temperature from inside
Knowledge-focused CompletedThis study tested whether a small, swallowable capsule can accurately measure body temperature in 30 hospitalized patients with blood cancers who have very low immunity (neutropenia). Researchers compared the capsule's temperature readings to standard ear thermometer measurements…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New imaging tracer could reveal how chemotherapy affects lymphoma blood vessels
Knowledge-focused CompletedThis study tested a special PET scan tracer called 18F-RGD-K5 in 21 people with lymphoma. The tracer highlights blood vessel growth (angiogenesis) in tumors. Scans were done before and after two rounds of chemotherapy to see how the tumors changed. The goal was to learn whether t…
Phase 2 • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Childhood leukemia chemo leaves lasting nerve damage in survivors
Knowledge-focused CompletedThis study looked at how common nerve damage is in adults who had vincristine chemotherapy for childhood leukemia. 467 survivors were assessed using a questionnaire about nerve symptoms. The goal was to understand how often and how severe this side effect is long after treatment …
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Leukemia cells may hide in frozen ovarian tissue, small study warns
Knowledge-focused CompletedThis pilot study looked at ovarian tissue from 9 young women with acute myeloid leukemia who had it frozen to preserve fertility before a stem cell transplant. Researchers checked the frozen tissue for any leftover leukemia cells. The goal was to see if the tissue might be safe t…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Do vaccines work as well in people with weak immune systems? new study investigates
Knowledge-focused CompletedThis study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutra…
Phase 4 • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Scientists create detailed map of Lymphoma's immune environment
Knowledge-focused CompletedThis study looked at 60 people with diffuse large B-cell lymphoma who were starting standard chemotherapy (R-CHOP). Researchers used advanced single-cell technology to analyze tumor and blood samples over two years. The goal was to find biomarkers that could help predict how well…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can a machine read pain in silent kids?
Knowledge-focused CompletedThis study tested whether a device called the ANI monitor can measure pain in sedated children aged 2 and older in the pediatric intensive care unit. Researchers watched how the device responded during painful care and compared it to a standard behavioral pain scale. The goal was…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Blood test could tailor leukemia drug dosing
Knowledge-focused CompletedThis pilot study looked at 20 adults with acute myeloid leukemia (AML) who were not healthy enough for strong chemotherapy. They received a standard combination of azacitidine and venetoclax. Researchers measured venetoclax levels in the blood at several time points to see if tho…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Telemedicine takes on lymphoma: a 350-Patient trial
Knowledge-focused CompletedThis study looked at whether using telemedicine (remote doctor visits) can improve how aggressive lymphomas are managed. The main goal was to see if patients got the right amount of chemotherapy on time. 350 patients from 10 hospitals took part. The study compared telemedicine su…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
CLL patients left in the dark: study maps treatment gaps after key drug fails
Knowledge-focused CompletedThis study looked at 152 adults with chronic lymphocytic leukemia (CLL) whose cancer stopped responding to a class of drugs called BTK inhibitors (like ibrutinib) and, in some cases, also to venetoclax. The goal was to understand what treatments doctors used next and how well the…
Sponsor: French Innovative Leukemia Organisation • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Italian study reveals Real-World impact of targeted leukemia drug
Knowledge-focused CompletedThis study looked back at the medical records of 84 people with acute lymphoblastic leukemia (ALL) who received a drug called anti-CD22 outside of clinical trials. The goal was to see how safe and effective the treatment was in everyday hospital use. Researchers collected informa…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Real-World study tracks patient adherence to multiple myeloma drug regimens
Knowledge-focused CompletedThis study looked at how faithfully adults with multiple myeloma (a type of blood cancer) follow their prescribed carfilzomib combination treatments in everyday medical practice. It included 359 patients who had already tried at least one prior therapy. The goal was to measure ad…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Blood cell study aims to predict transplant complications
Knowledge-focused CompletedThis study looked at 57 people who had a stem cell transplant for blood cancer. Researchers wanted to see if certain immune cells (iNKT cells) could help predict the risk of graft-versus-host disease (GVHD), a serious side effect. They measured these cells in the blood and the tr…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New scan method could improve fungal infection care in cancer patients
Knowledge-focused CompletedThis study looked at whether a special type of scan (PET/CT) can help doctors see if treatment for a serious fungal lung infection is working earlier than usual. It involved 51 adults with blood cancer and invasive pulmonary aspergillosis. The goal was to see if the scan results …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Blood test may spot bone damage in multiple myeloma
Knowledge-focused CompletedThis study looked at whether a substance called M-CSF in the blood can help identify bone lesions in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy contro…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New study observes how patients with mantle cell lymphoma fare on modern drugs
Knowledge-focused CompletedThis study created a registry of 227 adults with mantle cell lymphoma who had recently started a new type of therapy. Researchers tracked which treatments were used, how long patients stayed on them, and how patients rated their own quality of life. The goal was to gather real-wo…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
AI boosts cancer diagnosis speed in small study
Knowledge-focused CompletedThis study tested whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Ten doctors reviewed bone marrow samples with and without AI assistance. The goal was to see if AI improves …
Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Can we predict who bounces back after a bone marrow transplant?
Knowledge-focused CompletedThis study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Leukemia study checks if current treatments still work well
Knowledge-focused CompletedThis study looked back at the medical records of 400 adults with a specific type of acute myeloid leukemia called core binding factor (CBF) leukemia. Researchers wanted to see how well current treatments work and what factors affect outcomes, such as genetic mutations and signs o…
Sponsor: Acute Leukemia French Association • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
New telemedicine service brings nighttime care to children in ghana
Knowledge-focused CompletedThis study tested a new service that lets parents call for medical help at night and get medicine delivered to their home for their sick children. Over 1,200 children with common illnesses like pneumonia, diarrhea, or malaria took part in three communities in Ghana. The goal was …
Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Blood test norms for kids could end diagnostic delays
Knowledge-focused CompletedThis completed study measured normal tryptase levels in 402 children aged 0-18 to help doctors better diagnose mast cell disorders like mastocytosis and MCAS. Researchers used leftover blood from routine tests in children undergoing surgery. Knowing these normal ranges could redu…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:52 UTC
-
Blood cancer study seeks markers to match patients with best immunotherapy
Knowledge-focused CompletedThis completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By ide…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:43 UTC
-
PET scans may guide treatment of hidden fungal infection in cancer patients
Knowledge-focused CompletedThis study looked at whether a special type of PET scan can help doctors diagnose and treat a rare fungal infection of the liver and spleen in people with blood cancer or those who had a stem cell transplant. The infection often appears after severe neutropenia (low white blood c…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:07 UTC
-
Family DNA hunt aims to uncover myeloma risk genes
Knowledge-focused CompletedThis study collected blood samples from nearly 1,900 people in families where at least two members have a type of dysglobulinemia, including multiple myeloma, MGUS, or Waldenström's disease. Researchers will analyze the DNA to look for genetic variations that might increase the r…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:03 UTC
-
Hidden cancer cells in lymph nodes may force second thyroid surgery in many patients
Knowledge-focused CompletedThis study looked at 314 patients with small, early-stage papillary thyroid cancer who had surgery to remove half of the thyroid. During the operation, doctors checked nearby lymph nodes for hidden cancer spread. If cancer was found, the rest of the thyroid was removed in the sam…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:45 UTC